Specific antibody drug conjugates (ADCs) having KSP inhibitors

US11433140B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Dennis KIRCHHOFF · Berlin, DE
• Sandra BERNDT · Hohen Neuendorf, DE
• Lisa DIETZ · Wuppertal, DE
• Stephan MÄRSCH · Cologne, DE
• Stefanie HAMMER · Berlin, DE

Key dates

• Filing date: Dec 18, 2017
• Grant date: Sep 6, 2022
• Expiry date: May 19, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.